deferasirox (Exjade)
Jump to navigation
Jump to search
Introduction
oral iron-chelation therapy
Indications
Dosage
once a day, oral (on empty stomach)
Monitor
- serum ALT, serum AST, & serum bilirubin (plus serum alkaline phosphatase [Canada]) at baseline, every 2 weeks for the 1st month, then monthly[5]
Adverse effects
- acute renal failure, potentially fatal[2][4]
- cytopenias, including agranulocytosis, neutropenia, thrombocytopenia, potentially fatal[2]
- leukocytoclastic vasculitis, urticaria
- hypersensitivity reactions, including anaphylaxis, angioedema[2]
- liver impairment, including liver failure[4]
- gastrointestinal hemorrhage[4]
- greater number of adverse effects in patients > 60 years of age with myelodysplastic syndrome[3]
Drug interactions
- aluminum-containing antacids reduce absorption of deferasirox
Mechanism of action
Notes
cost $3000/month (2005)
More general terms
References
- ↑ Prescriber's Letter 13(1): 2006 Detail-Document#: http://prescribersletter.com/(5bhgn1a4ni4cyp2tvybwfh55)/pl/ArticleDD.aspx?li=1&st=1&cs=&s=PRL&pt=3&fpt=25&dd=220106&pb=PRL (subscription needed) http://www.prescribersletter.com
- ↑ 2.0 2.1 2.2 2.3 FDA MedWatch http://www.fda.gov/medwatch/safety/2007/safety07.htm#Exjade
- ↑ 3.0 3.1 FDA MedWatch Exjade (deferasirox) - Early Communication http://www.fda.gov/Safety/MedWatch/SafetyInformation/SafetyAlertsforHumanMedicalProducts/ucm183840.htm
- ↑ 4.0 4.1 4.2 4.3 FDA MedWatch Exjade (deferasirox): Boxed Warning http://www.fda.gov/Safety/MedWatch/SafetyInformation/SafetyAlertsforHumanMedicalProducts/ucm200850.htm
- ↑ 5.0 5.1 Prescriber's Letter 17(7): 2010 Recommended Lab Monitoring for Common Medications Liver Function Test Scheduling Detail-Document#: http://prescribersletter.com/(5bhgn1a4ni4cyp2tvybwfh55)/pl/ArticleDD.aspx?li=1&st=1&cs=&s=PRL&pt=3&fpt=25&dd=260704&pb=PRL (subscription needed) http://www.prescribersletter.com